PDCD1 and hypothyroidism: Our results, consistent with data of the vast majority of the cited papers, show significantly longer OS in patients who developed hypothyroidism as irAEs, suggesting that the dampening of PD-1 signaling pathway may be responsible for both endocrine toxicity and antitumor response, so that hypothyroidism may be seen as a marker of an enhanced therapeutic effect.